Now more than ever, we need collective advocacy to reverse steep funding cuts to the Lung Cancer Research Program (LCRP) caused by the FY25 Continuing Resolution’s reallocation within the Congressionally Directed Medical Research Program (CDMRP). LCRP provides critical funding and flexibility to researchers working on innovative breakthroughs for those affected by or at risk of lung cancer.

Join us in urging the House and Senate to restore funding in FY2026 and secure $60 million for the Lung Cancer Research Program in the Defense Appropriations Bill. 

Every voice and every message matters!